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Recoverin is a Ca2-regulated signal transduction
modulator found in vertebrate retina that has been
shown to undergo dramatic conformational changes
upon Ca2 binding to its two functional EF-hand motifs.
To elucidate the differential impact of the N-terminal
myristoylation as well as occupation of the two Ca2
binding sites on recoverin structure and function, we
have investigated a non-myristoylated E85Q mutant ex-
hibiting virtually no Ca2 binding to EF-2. Crystal struc-
tures of the mutant protein as well as the non-myristoy-
lated wild-type have been determined. Although the
non-myristoylated E85Q mutant does not display any
functional activity, its three-dimensional structure in
the presence of Ca2 resembles the myristoylated wild-
type with two Ca2 but is quite dissimilar from the myr-
istoylated E85Q mutant. We conclude that the N-termi-
nal myristoyl modification significantly stabilizes the
conformation of the Ca2-free protein (i.e. the T confor-
mation) during the stepwise transition toward the fully
Ca2-occupied state. On the basis of these observations,
a refined model for the role of the myristoyl group as an
intrinsic allosteric modulator is proposed.
Recoverin belongs to an ancient family of calcium-binding
proteins termed the neuronal calcium sensor family (1, 2) and
is mainly expressed in vertebrate photoreceptor cells (3, 4). The
23-kDa protein is composed of two domains, each of them
harboring one non-functional and one functional EF-hand he-
lix-loop-helix motif (5). Vertebrate photoreceptor cells respond
to illumination by a decrease of the intracellular transmitters
of excitation and adaptation, cGMP and Ca2, respectively. In
the dark, at high Ca2 concentration, the two functional EF-
hands of recoverin (EF-2 and -3) are occupied by Ca2 (6–8). In
this state, recoverin is able to inhibit the G-protein-coupled
receptor kinase GRK11 (rhodopsin kinase), thereby prolonging
the lifetime of photoexcited rhodopsin (9–12). Upon illumination,
decrease of cytoplasmic Ca2 causes this inhibition to be relieved.
This regulatory circuit is thought to be one out of several Ca2-
dependent mechanisms that control adaptation of phototrans-
duction to changing background light intensities (13, 14).
At its N terminus recoverin is heterogeneously acylated, the
prevailing modification being a myristoyl chain (15). The ob-
servation of a Ca2-dependent partitioning of recoverin to
membranes led to the proposal that it underwent a Ca2-
myristoyl switch (16). The mechanics of this switch were un-
raveled by determining the solution structures of Ca2-free and
Ca2-bound myristoylated recoverin via NMR spectroscopy. In
the Ca2-free state of recoverin (T state) the myristoyl moiety
is buried within a hydrophobic pocket, whereas in the Ca2-
bound form (R state), the acyl group is extruded and thus
available for interaction with other proteins or insertion into a
lipid bilayer (17–19). Moreover, the myristoyl chain has been
proposed to act as an intrinsic allosteric effector modifying the
conformational equilibrium between T and R states (20).
Ca2 binds to recoverin in a sequential fashion, i.e. occupa-
tion of high affinity EF-hand 3 is followed by filling of low
affinity EF-hand 2. An intermediate state with Ca2 bound
solely to EF-3 can be prepared using myristoylated recoverin
harboring the mutation E85Q, which virtually abolishes Ca2
binding to EF-hand 2. Recently the three-dimensional struc-
ture of the myristoylated E85Q mutant was determined by
NMR spectroscopy (21). It was shown to exhibit a hybrid fold
with the N- and C-terminal domains resembling the corre-
sponding portions of Ca2-free and Ca2-bound myristoylated
wild-type recoverin, respectively. Consequently, the myristoyl
group is still sequestered within a hydrophobic cavity and only
partially unclamped. Biochemical studies on the myristoylated
E85Q mutant confirmed that it can only bind one Ca2 at satu-
rating concentration (21, 22). Intriguingly, a fraction of myristoy-
lated E85Q recoverin binds to membranes already at low free
Ca2 (2–9 M), indicating that the presence of lipid bilayers may
shift the conformational equilibrium toward a form of the E85Q
mutant in which the myristoyl chain is exposed (22).
The presence of the N-terminal acyl group lowers the appar-
ent Ca2 affinity and adds cooperativity to the Ca2 binding
mode of recoverin (6). Because in the Ca2-saturated R state
the myristoyl group is exposed to the solvent, the x-ray struc-
ture of non-myristoylated recoverin in the presence of Ca2 has
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been suggested to represent a good approximation to the R
form of the myristoylated protein (23, 24). We therefore spec-
ulate that the non-myristoylated E85Q mutant may represent
a model of the myristoylated analog in the presence of mem-
branes. Despite the lack of evidence for involvement of non-
acylated recoverin in signal transduction, non-myristoylated
forms of the protein are valuable models to delineate the path-
ways of Ca2-induced conformational changes.
In the present study we address the impact of the myristoyl
group on the Ca2-dependent conformational transition in re-
coverin. To this end, we have determined the x-ray structure of
the non-myristoylated E85Q mutant and compared it to the
non-myristoylated wild-type as well as to the myristoylated
mutant published recently (21). Furthermore, to gain more
insight into the biochemical properties of the non-acylated
E85Q variant, we investigated key functional parameters such
as Ca2 binding, association with hydrophobic matrices, and
inhibition of rhodopsin kinase. Finally we asked how the bio-
chemical properties of the E85Q mutant correlate with the
structural information that we obtained on this mutant.
EXPERIMENTAL PROCEDURES
Preparation of Wild-type Recoverin, Mutant E85Q Recoverin, and
Rhodopsin Kinase—Preparation of recombinant non-myristoylated
forms of wild-type and mutant recoverin has been described previously
(22). The purification of rhodopsin kinase was performed by a modifi-
cation of a published procedure (25). Bovine rod outer segments (ROS,
100–200 mg of rhodopsin) were homogenized in low salt buffer (20 mM
Tris-HCl, pH 7.5, 2 mM MgCl2, 0.1 mM EDTA, 1 mM dithiothreitol
(DTT), 1 mM phenylmethylsulfonyl fluoride (PMSF)), illuminated at
4 °C for 10 min by a 150-watt white light source, and then ROS mem-
branes were pelleted. Rhodopsin kinase activity was extracted from
ROS membranes by washing three times in 10–15 ml of high salt buffer
(20 mM Tris-HCl, pH 7.5, 300 mM NaCl, 0.1 mM EDTA, 2 mM MgCl2, 1
mM DTT, and 1 mM PMSF) in the dark. The combined extract contain-
ing rhodopsin kinase activity was diluted with salt-free buffer (5 mM
Tris-HCl, pH 7.5, 0.1 mM EDTA, 2 mM MgCl2, 3 mM DTT, and 1 mM
PMSF) to a final concentration of 125 mM NaCl and was loaded onto a
heparin-agarose column. After a washing step with two bed volumes of
buffer (20 mM Tris-HCl, pH 7.5, 125 mM NaCl, 0.1 mM EDTA, 2 mM
MgCl2, 3 mM DTT, and 1 mM PMSF) rhodopsin kinase was eluted with
a solution containing 20 mM Tris-HCl, pH 7.5, 280 mM NaCl, 0.1 mM
EDTA, 2 mM MgCl2, 3 mM DTT, and 1 mM PMSF. The fractions con-
taining rhodopsin kinase activity were combined, diluted with salt-free
buffer to yield 100 mM NaCl, and applied to a Mono-Q (5/5) column.
Rhodopsin kinase activity was eluted with a linear gradient of 0–400
mM NaCl in 20 mM Tris-HCl, pH 7.5. All procedures were performed at
0–4 °C. The specific activity of purified rhodopsin kinase was 10–19
units/ml, with 1 unit being defined as the activity that catalyzes the
incorporation of 1 nmol of 32P per minute into light-activated rhodopsin
(25).
45Ca2 Binding Assay—Binding of 45Ca2 to wild-type recoverin and
the E85Q mutant was investigated as described previously (21, 22). In
summary, 50 or 100 M protein was dissolved in 20 mM HEPES-KOH,
pH 7.5, 100 mM NaCl, and 1 mM DTT and transferred to Centricon 10
devices (Amicon). Radioactive 45CaCl2 was added, the samples were
centrifuged for 1 min (7000 rpm, tabletop centrifuge Eppendorf model
5415), and radioactivity of the filtrate was counted (free Ca2). Next,
non-radioactive CaCl2 was added and the centrifugation procedure was
repeated. Protein-bound Ca2 versus free Ca2 was determined from
the excess Ca2 in the protein sample over that present in the ultrafil-
trate. Data were analyzed as described previously (22).
Phenyl-agarose Binding Assay—The phenyl-agarose binding assay
was performed according to a published procedure (16). Briefly, 2 M
wild-type recoverin or mutant E85Q were mixed with 100 l phenyl-
agarose (Sigma) and incubated at 37 °C (Eppendorf thermomixer 5436,
1,000 rpm) for 15 min in 20 mM HEPES, pH 7.5, 150 mM NaCl, 20 mM
MgCl2, 1 mM DTT, 3 mM EGTA, and 0–50 mM CaCl2 (total volume, 1000
l). The mixture was centrifuged for 15 min (14,000 rpm, table-top
centrifuge Eppendorf model 5415), and protein concentration in the
supernatant was determined by a Bradford protein assay (Bio-Rad).
Rhodopsin Kinase Assay—The assay mixture in a final volume of 50
l contained 10 M rhodopsin (urea-washed ROS), 20 mM Tris-HCl, pH
7.5, 2 mM MgCl2, 1 mM [-
32P]ATP (30–100 dpm/pmol), 1 mM DTT, 1 mM
PMSF, and 0.3 unit of rhodopsin kinase. Where appropriate, wild-type
recoverin or the E85Q mutant and a Ca2/bisaminobromophe-
noxyethane tetraacetate buffer were added (20). The reaction was ini-
tiated by addition of ATP, and samples were incubated in continuous
light for 30 min at 37 °C. Incubation was terminated by adding 1 ml of
10% (w/v) trichloroacetic acid. The resulting precipitate was collected by
centrifugation and washed 3–4 times with 1 ml of 10% trichloroacetic
acid; the pellet was used for Cerenkov counting.
Recoverin Crystallization—Non-myristoylated recombinant bovine
recoverin was crystallized using the hanging-drop setup in a buffer
containing 100 mM Tris-HCl, pH 8.0, 1 mM CaCl2, and 1 mM MgCl2 with
the reservoir solution additionally containing 70–80% saturated am-
monium sulfate. Crystals measuring 150–250 m in each dimension
grew within 4–6 weeks under these conditions.
Data Collection—Crystallographic datasets were collected at 100 K.
Because crystals could not be grown in the presence of cryoprotectants,
they were soaked in reservoir solution containing 5, 10, and 15% (v/v)
glycerol for 10 min each and 30% for 10 s prior to cryocooling.
Native data were recorded at beamline ID14-1 of the European
Synchrotron Radiation Facility (Grenoble, France) tuned to a wave-
length of 0.934 Å on an ADSC-Q4R detector (ADSC-Quantum). Data
processing, including reflections up to 1.5- and 1.9-Å resolution for wild-
type and mutant, respectively, was carried out using MOSFLM (26) and
SCALA, the latter of which is part of the CCP4 software suite (27).
Structure Solution—Both recoverin structures were determined by
molecular replacement using a single dataset each. The crystal struc-
ture of non-myristoylated recombinant bovine recoverin reported pre-
viously (23) was used as a starting model for refinement of the wild-type
structure. Following preliminary refinement using the CNS software
package (28), all regions poorly defined in electron density were re-
moved from the model and re-established in an iterative process, in-
cluding several cycles of positional refinement and manual rebuilding
using the program O (29). To minimize model bias in the refinement
process, electron density was modified using the DM package (CCP4),
including solvent flattening, histogram mapping, and Sayre’s equation.
This finally allowed for portions of the structure not well-defined in 2Fo 
Fc maps (i.e. residues 2–6 and 201–202) to be built as well. A total of 85
crystallographic water molecules could be determined in the structure.
The resulting improved wild-type recoverin model served as a start-
ing point for determination of the E85Q mutant structure, which was
performed using essentially the same strategy. In this case, residues
2–6, 75–77, and 198–202 could not be properly defined even by the use
of density modification algorithms. The number of water molecules in
this structure was 76. For statistics on data collection and refinement
refer to Table I.
According to Ramachandran plots generated with PROCHECK
(CCP4), both models exhibit good geometry with 98.4 and 100%, respec-
tively, of the residues in the allowed regions. Exceptions in the wild-
type structure include serines 4 and 6 located in the N-terminal tail
poorly defined in the 2Fo  Fc map and aspartate 74, which is part of
the Ca2 binding EF-2 loop. Figures were generated using MOL-
SCRIPT (30) and RASTER3D (31) using secondary structure assign-
ments as given by the DSSP program (32). Surface representations
were prepared with VMD (33). For depicting solution structures deter-
mined by NMR spectroscopy the individual structure exhibiting the
lowest r.m.s. deviation from the mean, as determined with MOLMOL
(34), was selected from the ensemble. Calculation of EF-hand interheli-
cal angles was performed using the program INTERHLX (obtained
from nmr.uhnres.utoronto.ca/ikura/datasoft.html).
RESULTS
Ca2 Binding Properties of Recoverin Variants—To assess
the functional activity of non-myristoylated E85Q mutant re-
coverin, we first investigated its ability to bind radioactive
45Ca2 (Fig. 1). One Ca2 ion is bound to the mutant protein
with an apparent dissociation constant (KD) of 0.26 M, and
binding is saturated above 10 M. These observations are in
agreement with data reported recently (KD  0.15 M (21)). To
assure our method worked properly, we repeated measure-
ments on non-acylated wild-type recoverin as a control showing
that it binds two Ca2 non-cooperatively with an apparent KD
of 0.21 and 6.2 M, respectively (Fig. 1). Our results confirmed
previous observations indicating that EF-hand 3 is the high
affinity Ca2 binding site in recoverin, irrespective of the myr-
istoylation state (6).
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Interaction with Phenyl-agarose—Binding of recoverin to
phenyl-agarose is thought to depend on the Ca2-induced ex-
posure of hydrophobic residues and not on the presence of the
myristoyl group (16). We applied this assay to test whether the
non-myristoylated E85Q variant could bind to phenyl-agarose
in a fashion similar to the wild-type (Fig. 2). In fact, the mutant
protein did not display any binding activity at all. By contrast,
wild-type recoverin included as a control bound to the hydro-
phobic matrix with half-saturation occurring at 1.5 M Ca2.
Inhibition of Rhodopsin Kinase—One more characteristic
feature of recoverin is its capability of inhibiting rhodopsin
kinase in a Ca2-dependent manner (9–11, 35, 36). Myristoy-
lation of recoverin is dispensable for this activity, because the
non-acylated protein inhibits rhodopsin kinase in a manner
very similar to the myristoylated form (37). Thus, it is sug-
gested that calcium triggers exposure of an interaction site that
mediates inhibition of GRK1 by recoverin and is different from
its N-terminal myristoyl group. We tested whether the mutant
could inhibit rhodopsin kinase in a Ca2-dependent manner.
As shown in Fig. 3, the E85Q mutant was not capable of
inhibiting GRK1 to a significant extent. In contrast, the non-
myristoylated wild-type used as a positive control inhibited
rhodopsin kinase as expected.
Crystal Structure of Wild-type Recoverin and the E85Q Mu-
tant—For elucidating the role of the myristoyl modification as
an intrinsic modulator of the Ca2-induced conformational
transition in recoverin, structural studies on non-myristoy-
lated analogs are particularly useful. As a first approach, to
TABLE I
X-ray crystallographic data
Rmeas  h [Nh/(Nh  1)]
1⁄2 i Ii,h  Ih/hiIi,h according to Ref. 51, also termed redundancy-independent merging R factor (Rr.i.m.) with Ii,h
representing the ith out of Nh measurements and Ih the mean of all observations of Ih. For calculation Rfree, 5% of all reflections were reserved.
Recombinant bovine recoverin
Wild-type E85Q mutant
Data collection
Space group I4 I4
Cell dimensions
a  b, c (Å) (T  100 K) 84.05, 59.18 84.33, 58.81
Resolution (Å) 1.50 1.90
Beamline Grenoble ID14-1 Grenoble ID14-1
Detector ADSC-Q4R ADSC-Q4R
Wavelength (Å) 0.934 0.934
Unique reflections 33042 16253
Average multiplicity 3.8 3.8
Completeness (%) 99.9 (100.0)a 99.7 (100.0)a
Rmeas (%) 6.8 (42.2)
a 8.7 (20.8)a
I/(I) 5.2 (2.0)a 4.7 (3.1)a
Refinement
Resolution (Å) 48.39-1.50 59.63-1.90
Rwork (%) 24.9 24.0
Rfree (%) 25.0 24.9
Residue range 2-202 7-74, 78-197
Number of atoms
Protein 1638 1542
Water 85 76
Ca2 1 1
r.m.s. deviation
Bonds (Å) 0.007 0.007
Angles (°) 1.329 1.383
E85Q versus wt (backbone r.m.s. deviation) (Å) 0.30
a Numbers in parentheses indicate the value for the highest resolution shell.
FIG. 1. 45Ca2 binding to non-myristoylated forms of recov-
erin. Wild-type recoverin () and the E85Q mutant (E) were incubated
with increasing free Ca2. Solid lines represent the best fit to the
two-site model (KD1  0.21 M and KD2  6.2 M for non-myristoylated
wild-type recoverin) as described in ref. 6. Binding of 45Ca2 to the
E85Q mutant yielded a KD of 0.26 M.
FIG. 2. Binding of non-myristoylated wild-type recoverin ()
and the E85Q variant (E) to phenyl-agarose as a function of Ca2
concentration. Binding was half-maximal at 1.5 M Ca2 for the
wild-type protein.
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establish a positive control system, we have re-investigated the
crystallographic structure of recombinant non-myristoylated
bovine recoverin to a higher resolution (1.5 Å) than has been
described previously (1.9 Å (23)). As a result, we were able to
trace backbone and side-chain density in a larger portion of the
molecule, particularly in the N- and C-terminal parts and the
EF-2 loop. In the extreme termini (residues 2–6 and 201–202),
use of conventional 2Fo  Fc and Fo  Fc maps did not allow for
satisfactory density allocation. However, based on density mod-
ification strategies, tentative coordinates are included for these
stretches as well. The overall fold of the molecule is mostly
identical to the published structure with a root mean square
(r.m.s.) deviation of 0.45 Å for main-chain atoms and 1.03 Å for
all non-hydrogen atoms. Likewise, the EF-2 Ca2 binding site
was found to be unoccupied despite the presence of 1 mM Ca2
in the crystallization mother liquor. This is probably due to the
high concentration of ammonium sulfate (approx. 3 M) in the
solution, because it is well established that high ionic strength
leads to electrostatic screening of ionic binding sites. Thus the
Ca2 activity is decreased into a range supporting binding to
the high affinity EF-3 but not to the low affinity EF-2 site.
Moreover, a model calculation of free Ca2 in the presence of 3
M sulfate lead to an estimate well below 1 M, which is clearly
insufficient for Ca2 binding to EF-2. The absence of Ca2 in
EF-2 in the crystal structures should therefore be viewed as a
reflection of the ion concentrations in the samples and not an
indication of an artifact due to crystal packing interactions.
Although the non-liganded EF-2 loop is quite well defined in
our crystal structure (mean atomic B factor 22.4 Å2 for residues
72–82 compared with 21.7 Å2 for the entire structure), we
cannot exclude that it exhibits increased flexibility in solution.
Using crystallization conditions similar to those for the wild-
type protein, crystals of the E85Q mutant diffracting to 1.9 Å
were obtained. In this case, the entire polypeptide chain could
be traced with the exception of residues 2–6, 75–77, and 198–
202, which are poorly defined in electron density. The overall
fold of the mutant protein turned out to be very similar to our
wild-type structure with an r.m.s. deviation over the portions
well-defined in both structures (residues 7–74 and 78–197) of
0.30 Å for main-chain atoms and 0.65 Å for all non-hydrogen
atoms. This similarity is not surprising, because even the crys-
tal structure of wild-type recoverin does not show any Ca2
binding to EF-hand 2 (see above), which is disabled in the E85Q
mutant. As has already been noted for the wild-type crystal
structure, this fold is quite similar to the solution structure of
the myristoylated protein with two Ca2 bound (19). During
the course of the present study, an NMR structure of the
myristoylated E85Q mutant was published (21). Intriguingly,
there are striking differences between the two structures of
E85Q (Fig. 4).2 In the myristoylated variant (shown in red), the
conformation of the N-terminal domain is similar to the solu-
tion structure of the Ca2-free myristoylated wild-type protein,
i.e. the T state (18), whereas in our non-myristoylated mutant
(blue) it resembles the R state fold of the myristoylated wild-
type with two Ca2 (19). Specifically, the relatively limited
2 Comparative structural representations included in this report dis-
play crystallographic structures along with NMR structures. We are
aware of the possibility of artifacts, e.g. due to crystal packing interac-
tions (38), that in certain cases may limit comparability of structures
determined by different methods. However, due to the large extent of
the majority of structural differences we refer to, we are confident that
the conclusions drawn are nonetheless significant.
FIG. 3. Inhibition of rhodopsin kinase by non-myristoylated
forms of recoverin. Phosphorylation of rhodopsin was measured as a
function of free Ca2 concentration in the presence of 30 M non-
myristoylated wild-type () and E85Q mutant recoverin (E). The solid
line represents a fit according to the Hill model yielding the following
values of IC50 (Ca
2) and Hill coefficient n for non-myristoylated wild-
type recoverin: IC50  0.6 M, n  0.96. No significant inhibition was
observed in the presence of the E85Q variant.
FIG. 4. Stereo representation of the three-dimensional struc-
ture of myristoylated (red (21)) and non-myristoylated (blue;
this study) E85Q mutant recoverin. To highlight differences in the
N-terminal domains, both structures have been aligned with respect to
the C-terminal part (residues 100–185) resulting in a main-chain r.m.s.
deviation of 1.99 Å for this region. EF-hands are labeled I through IV
with a and b indicating the entering and exiting -helices, respectively.
Co-ordinates of the Ca2 ion (gray) are taken from the structure of the
non-myristoylated protein.
FIG. 5. Stereo view of C traces of myristoylated recoverin
with two Ca2 (lighter colors (19)) and the non-myristoylated
form with one Ca2 (darker colors; this study). Structures have
been aligned with respect to the C-terminal domains (residues 100–
185, main-chain r.m.s. deviation 1.86 Å), which have been omitted for
clarity. EF-hands 1 and 2 are colored blue and red, respectively. Regions
undergoing significant changes upon Ca2 binding are indicated. See
text for details.
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conformational changes in the C-terminal domain as well as
rotation of the two domains with respect to each other near
Gly96, both of which are believed to be induced by Ca2 binding
to EF-3, are common to both structures. In contrast, rotation
around Gly42 (indicated by an arrowhead in Fig. 4), leading to
a considerable displacement of the N-terminal -helix and the
entering helix of EF-1, is only observed in the non-acylated
mutant. These observations suggest that the unmodified pro-
tein possesses the intrinsic capability of undergoing almost the
entire Ca2-induced conformational transition upon Ca2
binding to EF-3, whereas in the myristoylated form the N-
terminal domain is locked in the T state until Ca2 is bound to
EF-2.
Because in Ca2-saturated recoverin the myristoyl group is
extruded and does not significantly interact with the protein
moiety (19), we decided to use the NMR structure of the myr-
istoylated protein with two Ca2 as a model for the correspond-
ing non-myristoylated analog. Although this is a reasonable
assumption, equivalence of tertiary folds cannot be unequivo-
cally proven in the absence of a structure of Ca2-saturated
non-myristoylated recoverin. This stated, the differences be-
tween our crystallographic structure of non-myristoylated re-
coverin with one Ca2 and the solution structure of the myris-
toylated protein with two Ca2 should be mainly related to
Ca2 binding to EF-2. The most significant structural alter-
ations are highlighted in Fig. 5. Establishment of the Ca2
co-ordination sphere requires “flipping” of the Ca2-binding
loop (residues 72–82, region 1), which is associated with a
decrease in the EF-2 interhelical angle (Table II, below). The
resulting movement of the domain linker (residues 95–101,
region 2) by 5 Å causes a steric clash with a stretch of
residues connecting the N-terminal -helix to the entering
helix of EF-1 (residues 18–24, region 3), which forces a con-
certed movement of this loop. Consequently, the orientation of
the N-terminal helix (region 4) also changes considerably. Com-
parison of these two recoverin structures thus enables us to
trace structural implications of Ca2 binding to EF-2 through-
out the entire domain. Moreover, as the structure of the non-
acylated E85Q mutant is virtually identical to the non-acylated
wild-type, both of which contain one Ca2 bound to EF-3, these
effects of EF-2 occupation probably account for the functional
inactivity of the mutant, as discussed below.
The interhelical angle defined by the entering and exiting
helices is a sensitive indicator of conformational changes in
EF-hand modules (39). Table II gives a compilation of this
parameter for EF-hands 1 through 4 for all recoverin struc-
tures currently available. The angle defined by the exiting helix
of EF-2 and the entering helix of EF-3 has been included for
monitoring the arrangement of the N-terminal domain relative
to the C-terminal portion. The values listed support our con-
clusion that, upon occupation of EF-3 in the non-myristoylated
protein, EF-1 adopts a configuration reminiscent of the sterical
arrangement in myristoylated recoverin with two Ca2. At the
same time, the interhelical angle in EF-2 is similar to the value
in the myristoylated E85Q mutant and is thus representative
of a non-liganded EF-2 in the T/R intermediate state. The
difference in EF-2 interhelical angle between these structures
on the one hand and the Ca2-free protein on the other may
TABLE II
Selected interhelical angles in recoverin
Comparative overview showing interhelical angles in EF-hand motifs 1 through 4 as well as the inter-domain angles between the EF-2 exiting
helix and the EF-3 entering helix (italic) for different recoverin structures. Angles were computed with INTERHLX using secondary structure
assignments as given by the DSSP algorithm. Boldface indicates values for Ca2-occupied EF-hands. For NMR structures, values are given as
mean  S.D. of the entire ensemble.
Non-myr. recoverin (x-ray) Myr. recoverin (NMR)
Rec
-1 Ca-
Reca
-1 Ca-
Rec[E85Q]
-1 Ca-
Myr-Recb
-0 Ca-
Myr-Rec[E85Q]c
-1 Ca-
Myr-Recd
-2 Ca-
EF-1 108 108 108 170  2 167  3 115  6
EF-2 130 129 130 136  3 125  3 122  6
EF-3 103 101 103 119  2 87  3 91  4
EF-4 103 99 103 99  3 91  5 88  3
Inter-domain 96 96 96 166  2 109  4 102  4
a Ref. 23; b Ref. 18; c Ref. 21; d Ref. 19.
FIG. 6. Hydrophobicity in solvent-
accessible surfaces of different re-
coverin variants. Apolar regions are
highlighted in yellow. Upper row: non-
myristoylated wild-type (Rec) and mutant
(Rec[E85Q]) recoverin investigated in this
study. Bottom row: myristoylated wild-
type (myr-Rec (18, 19)) and mutant (myr-
Rec[E85Q] (21)) variants. The number of
Ca2 ions bound to each protein is indi-
cated. The blue circle marks a hydropho-
bic patch exposed in some of the struc-
tures. See text for details.
Role of Myristoylation in Recoverin22976
 at R
sch Cntr Julich Res library on August 6, 2007 
w
w
w
.jbc.org
D
ow
nloaded from
 
indicate a slight conformational change in EF-2, which is as-
sociated with Ca2 binding to EF-3 and the resulting re-ar-
rangement of the domain interface. With respect to the C-
terminal domain, interpretation of the results is more
complicated. For example, the angle of EF-3 in the crystal
structures containing one Ca2, although clearly different from
the unoccupied EF-3 in Ca2-free myristoylated recoverin, is
still not identical to the myristoylated structures with one or
two Ca2 ions. Moreover, the extent of the rotation around
Gly96 in non-myristoylated E85Q recoverin, which ultimately
results from Ca2 binding to EF-3, is more similar to the
myristoylated protein with two Ca2 than to the myristoylated
E85Q mutant with one Ca2. These observations indicate that
the increased conformational rigidity of the N-terminal domain
in the presence of the buried myristoyl group on the one hand
limits the magnitude of the domain rotation but on the other
hand in some way facilitates the Ca2-induced “opening” move-
ment of EF-3. Thus, the bidirectional transfer of conforma-
tional information across the domain interface is significantly
modulated by the presence of the N-terminal myristoyl moiety.
DISCUSSION
The three-dimensional structure of non-myristoylated re-
combinant bovine recoverin has been determined by x-ray crys-
tallography almost a decade ago (23). In the meantime, solution
structures of the myristoylated protein in the Ca2-free state
(18) as well as with Ca2 bound to EF hands 2 and 3 (19) have
been published. These data revealed that binding of Ca2 es-
sentially modifies the equilibrium between two dramatically
different conformational states commonly referred to as the T
and R state. This transition includes two major rotational
components among glycine residues at positions 42 and 96.
Recently, Ames et al. (21) described the structure of the myr-
istoylated E85Q mutant determined by NMR spectroscopy in
the presence of 1 mM Ca2. They found the protein to exhibit a
hybrid structure with the N- and C-terminal domains adopting
an overall fold resembling the corresponding portions of Ca2-
free and Ca2-bound myristoylated recoverin, respectively. Al-
though these studies allowed for the different conformational
states of acylated recoverin to be described in detail, the precise
role of the N-terminal myristoyl modification in the context of
the Ca2-induced conformational transition has remained
unclear.
In this study, we have determined the crystallographic struc-
ture of non-myristoylated recoverin bearing the E85Q substi-
tution which virtually abolishes Ca2 binding to EF-hand 2. An
improved structure of the wild-type protein at 1.5-Å resolution
allowed us to trace larger portions of the molecule than was
previously possible. The overall fold of the wild-type and mu-
tant recoverin is almost identical, which can be explained by
the absence of Ca2 binding to EF-2 even in the wild-type
under the crystallization conditions employed. Thus, in both
cases the protein is trapped in an intermediate state reflecting
conformational changes induced by Ca2 binding to EF-3. Sev-
eral conclusions can be drawn from the intriguing similarity
between these two structures and the solution structure of the
fully Ca2-occupied myristoylated protein.
First, the Ca2-induced conformational transition initially
FIG. 7. Arrangement of side chains
critical for interaction with rhodop-
sin kinase (as defined in Ref. 41). Res-
idues probably involved in the binding in-
terface according to these authors are
colored in red, those of minor significance
in orange. Abbreviations are as in Fig. 6.
FIG. 8. C trace superposition (identical to Fig. 5 with 180°
rotation) of non-myristoylated recoverin with one Ca2 (darker
colors) and myristoylated recoverin with two Ca2 (lighter col-
ors) showing positional re-arrangement of hydrophobic resi-
dues forming the patch defined in Fig. 6 (yellow backbone) and
of side chains probably (light and dark red) and possibly (light
and dark orange) involved in rhodopsin kinase inhibition (see
Fig. 7).
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observed in the NMR structures of myristoylated recoverin
appear for the most part not to require Ca2 binding to EF-2 in
the non-myristoylated protein. Instead, upon Ca2 binding to
EF-3 both domains adopt a characteristic R state fold, includ-
ing rotational movements about Gly42 and Gly96 (Fig. 4). This
conclusion relies on the assumption that in the Ca2-free state
recoverin structure is largely independent of the myristoyla-
tion state. Unfortunately, structural information on non-acy-
lated Ca2-free recoverin is currently unavailable. Nonethe-
less, there are several lines of indirect evidence supporting this
view. Dizhoor et al. (20) have analyzed the susceptibility of
acylated and non-acylated recoverin to tryptic cleavage in the
presence and absence of Ca2. They found Ca2 to increase
resistance toward degradation, this effect being even more
pronounced with the non-acylated protein. In a CD-spectro-
scopic study performed by Kataoka et al. (40), the Ca2-induced
increase in ellipticity at   208 nm and   222 nm was
reported to be independent of the myristoylation state. Finally,
binding of the fluorescent dye 1-anilinonaphthalene-8-sulfon-
ate by recoverin increases dramatically upon Ca2 binding in
both the myristoylated and the non-myristoylated state (41).
These data indicate that the Ca2-induced conformational
changes in unmodified recoverin are at least comparable to
those observed for the native acylated protein. Of course, we
cannot exclude the possibility that the presence of the myris-
toyl moiety may induce minor structural changes in the Ca2-
free protein, the NMR structure of which has revealed a tight
interaction of the acyl chain with its hydrophobic pocket. In-
deed, when comparing deuterium exchange rates of myristoy-
lated and non-myristoylated recoverin in the presence and
absence of Ca2, Neubert et al. (42) found the myristoylation
state to affect isotope exchange in certain recoverin fragments,
although for both the myristoylated and the non-myristoylated
protein, significant effects of Ca2 binding were observed. At-
tempts to crystallize Ca2-free non-myristoylated recoverin
have thus far been unsuccessful.
A second conclusion from our data concerns the role of the
myristoyl group. As stated above, the conformational changes
in the C-terminal domain induced by occupancy of EF-3 and the
subsequent reorganization at the domain interface tend to de-
stabilize the T state in the N-terminal part even in the absence
of Ca2 binding to EF-2. This effect is counterbalanced in the
presence of the myristoyl moiety, which is able to stabilize the
arrangement of the N-terminal domain in the Ca2-free state.
As a result, in the myristoylated protein binding of Ca2 to
EF-2 is essential to shift the conformational equilibrium to-
ward the R state. In this model, Ca2 binding to EF-2 would not
directly drive the rotation about Gly42, resulting in the N
terminus “pulling” the myristoyl group out of its hydrophobic
pocket, as previously suggested, but is likely to destabilize the
hydrophobic interactions of the myristoyl with its environment,
rendering the buried state thermodynamically less favorable.
This would ultimately allow the intrinsic tension of the domain
to be relieved, partly by means of the aforementioned rotation.
In the absence of the myristoyl modification, the structural
impact of Ca2 binding to EF-2 is greatly reduced (Fig. 5).
Nonetheless, it is absolutely required to attain the R state,
because the E85Q mutant neither displays binding to phenyl-
agarose (Fig. 2) nor is able to inhibit rhodopsin kinase (Fig. 3).
A thorough comparison of available recoverin structures of-
fers possible explanations for this behavior. Fig. 6 illustrates
the pattern of polarity on the solvent-accessible surface com-
puted for various recoverin structures. Upon Ca2 binding, the
myristoylated protein exposes a large hydrophobic patch (blue
circle), which is made up of aromatic (Phe23, Trp31, Phe35,
Phe56, Phe57, Phe83) and aliphatic (Leu28, Ile44, Leu81, Leu90)
side chains and is surrounded by charged and polar residues.
Although not discernible in the myristoylated E85Q mutant, in
the non-myristoylated structures this patch is formed in its
general outline, but the pattern still changes further in the
fully Ca2-occupied protein. Specifically, the terminal hydroxyl
oxygen of Tyr86, which is located in the center of the hydropho-
bic patch and is readily solvent-accessible in non-myristoylated
recoverin with one Ca2, becomes almost completely buried
upon Ca2 incorporation into EF-2. Because this hydrophobic
region is a good candidate for mediating the Ca2-induced
binding of recoverin to phenyl-agarose, these observations may
explain why the E85Q mutant (largely irrespective of myris-
toylation) does not efficiently bind to this hydrophobic matrix
in the presence of Ca2.
A similar approach was used to understand the different
capabilities of the same recoverin variants to inhibit rhodopsin
kinase in a Ca2-dependent manner. In a recent mutational
study on the frog recoverin homolog S-modulin, Tachibanaki et
al. (43) identified seven conserved amino acid residues that
were proposed to constitute an interaction surface for rhodop-
sin kinase. Based on the degree of preservation of Ca2-in-
duced conformational changes as assessed by CD spectroscopy,
the authors defined “probable” (residues Phe23, Glu27, Phe56,
and Thr93) and “possible” (residues Thr21, Phe57, and Lys101)
interaction sites. In Fig. 7 these groups of residues (colored red
and orange, respectively) are mapped to the solvent-accessible
surface in the recoverin structures under consideration. It is
evident that these crucial side chains localize near each other
only upon Ca2 binding to EF-2 and EF-3 in the myristoylated
protein. The conformational transition, which is allowed in the
acylated E85Q mutant upon EF-3 occupation, does not estab-
lish the interaction surface, and even the non-acylated wild-
type and mutant proteins containing one Ca2, while display-
ing an overall fold resembling the native R state, do not present
the same sterical arrangement of these critical residues. Fig. 8
emphasizes individual side-chain displacements occurring in
the N-terminal domain of non-myristoylated recoverin upon
binding of Ca2 to EF-2 and thus accounting for the differences
in surface properties between Rec * 1 Ca and myr-Rec * 2 Ca
shown in Figs. 6 and 7.
The three-dimensional structures of several other members
of the neuronal calcium sensor family have been determined
thus far. These include GCAP-2 (44), neurocalcin (45), human
(46), and yeast frequenin (47). Although the overall topology of
their folds resembles the structure of recoverin, they also differ
in several aspects. For example, an attached myristoyl group
can adopt diverse functions, and although some proteins such
as recoverin, hippocalcin, and neurocalcin  exhibit a Ca2-
myristoyl switch, others like GCAP-1, GCAP-2, and frequenin
apparently do not (48–50). Diversity of Ca2 signaling via
neuronal calcium sensor proteins is also mirrored by the vari-
ety of target proteins, including various kinases, membrane-
bound guanylate cyclases, adenylate cyclases, ion channels,
and cytoskeletal proteins. Our results indicate that subtle
changes in surface properties can dramatically alter the bio-
chemical characteristics of recoverin, such as interaction with
phenyl-agarose and rhodopsin kinase inhibition. In line with
these conclusions, minor differences in surface exposition of
amino acid side chains might well account for the diversity of
neuronal calcium sensor signaling.
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